In the placebo + MTX group, changes in ICAM-1 and CRP levels were significantly correlated with the number of joints with active arthritis at week 14 (r = 0.64, p < 0.0001; r = 0.38, p = 0.004; respectively) (data not shown). This evidence concerns the gene CRP and Arthritis.